Endovastec(SH:688016) Sou Hu Cai Jing·2026-01-19 14:59Core Viewpoint - The company, Xinmai Medical, has announced the use of part of its temporarily idle raised funds for cash management, ensuring that this will not affect its investment plans and will support operational liquidity and project funding needs [1]. Group 1: Stock Performance - As of January 19, 2026, Xinmai Medical's stock closed at 96.73 yuan, down 1.28% from the previous trading day, with a total market capitalization of 11.923 billion yuan [1]. - The stock opened at 97.93 yuan, reached a high of 98.5 yuan, and a low of 96.66 yuan, with a trading volume of 1.41 billion yuan and a turnover rate of 1.17% [1]. Group 2: Fund Management Announcement - The company held its 12th meeting of the 3rd Board of Directors on January 19, 2026, where it approved the use of up to 1 billion yuan of temporarily idle raised funds for cash management [1]. - The investment will focus on high safety and liquidity products, including structured deposits, notice deposits, time deposits, large certificates of deposit, and income certificates [1]. - The usage period for these funds is within 12 months from the date of board approval, and the funds can be rolled over [1]. - The company has committed that this action will not impact the normal execution of its fundraising investment plans, and any earnings will be used to cover funding shortfalls for investment projects and daily operational liquidity [1].